INMUNE BIO INC. Related Party Tax Expense Effect of Change in Allocation Methodology
INMUNE BIO INC. (INMB) reported Related Party Tax Expense Effect of Change in Allocation Methodology of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology · last filed 2023-05-03
- INMUNE BIO INC. related party tax expense effect of change in allocation methodology for the quarter ending 2023-03-31 was $0.00.
| Period end | Related Party Tax Expense Effect of Change in Allocation Methodology 3 month | Related Party Tax Expense Effect of Change in Allocation Methodology 12 month |
|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |